{"id": "314533ae-f961-3dc0-9be8-e0e4fa67bac6", "ticker": "BAYN.DE", "url": "https://finance.yahoo.com/news/viatris-stock-rises-q2-earnings-150000597.html", "title": "Viatris Stock Rises as Q2 Earnings & Revenues Beat Estimates", "summary": "VTRS beats on Q2 estimates with strength in branded drugs and growth in Greater China, lifting shares.", "published_at": "2025-08-07T15:00:00Z", "sentiment": "neutral", "confidence": 1.0}
{"id": "1e063d88-0e8c-3782-828c-0ba343b34f0e", "ticker": "BAYN.DE", "url": "https://finance.yahoo.com/news/bayer-second-quarter-2025-earnings-125923709.html", "title": "Bayer Second Quarter 2025 Earnings: EPS Misses Expectations", "summary": "XTRA:BAYN 1 Year Share Price vs Fair Value Explore Bayer's Fair Values from the Community and select yours Bayer...", "published_at": "2025-08-07T12:59:23Z", "sentiment": "positive", "confidence": 1.0}
{"id": "c443dbc2-84b3-3f78-b537-2881e458ac1d", "ticker": "BAYN.DE", "url": "https://www.pharmaceutical-technology.com/news/why-liverpools-wirtz-is-causing-concern-at-big-pharma-company-bayer/", "title": "Why Liverpool’s Wirtz is causing concern at big pharma company Bayer", "summary": "Bayer disclosed that its Q2 earnings were inflated by transfer fees at its German football club Bayer Leverkusen.", "published_at": "2025-08-07T11:44:20Z", "sentiment": "positive", "confidence": 1.0}
{"id": "930caa45-c1fa-3717-ab55-e627dedb7af0", "ticker": "BAYN.DE", "url": "https://www.clinicaltrialsarena.com/news/clinical-trial-supply-chains-in-the-us-navigate-pharma-tariffs/", "title": "Clinical trial supply chains in the US navigate pharma tariffs", "summary": "The 2025 Clinical Trial Supply West Coast conference will gather experts to discuss US trial operations in a shifting tariff landscape.", "published_at": "2025-08-07T09:15:57Z", "sentiment": "negative", "confidence": 1.0}
{"id": "e1062832-8561-32f0-9226-6aa7e4599044", "ticker": "BAYN.DE", "url": "https://www.wsj.com/business/basic-materials-roundup-market-talk-931de748?siteid=yhoof2&yptr=yahoo", "title": "Basic Materials Roundup: Market Talk", "summary": "Find insight on Glencore, Lindian Resources and more in the latest Market Talks covering Basic Materials.", "published_at": "2025-08-06T21:30:00Z", "sentiment": "negative", "confidence": 1.0}
{"id": "75793345-4a7f-3a28-b8c3-1966defd578a", "ticker": "BAYN.DE", "url": "https://www.wsj.com/health/health-care-roundup-market-talk-2bae99cf?siteid=yhoof2&yptr=yahoo", "title": "Health Care Roundup: Market Talk", "summary": "Find insight on Bayer, Novo Nordisk, Bayer, Pfizer and more in the latest Market Talks covering Health Care.", "published_at": "2025-08-06T16:28:00Z", "sentiment": "negative", "confidence": 1.0}
{"id": "3788f27a-f24a-3488-a2d3-f6b2bc740ecd", "ticker": "BAYN.DE", "url": "https://finance.yahoo.com/news/rxrx-q2-loss-wider-expected-154800952.html", "title": "RXRX Q2 Loss Wider Than Expected, Revenues Rise Y/Y, Stock Down", "summary": "Recursion Pharmaceuticals stock drops as Q2 loss widens and pipeline shake-up continues, despite revenues boost from Sanofi milestone.", "published_at": "2025-08-06T15:48:00Z", "sentiment": "neutral", "confidence": 0.9995}
{"id": "e40b4dc7-2eb7-37dd-ae91-cd5aeef36cd8", "ticker": "BAYN.DE", "url": "https://finance.yahoo.com/news/bayer-beats-q2-earnings-sales-143300506.html", "title": "Bayer Beats on Q2 Earnings and Sales, Raises '25 Adjusted Sales View", "summary": "BAYRY beats on Q2 earnings and raises 2025 sales outlook (on a currency-adjusted basis) as pharma growth offsets currency and Xarelto headwinds.", "published_at": "2025-08-06T14:33:00Z", "sentiment": "neutral", "confidence": 1.0}
{"id": "a95de649-31ed-36cb-8f5f-b7a968ce5cd7", "ticker": "BAYN.DE", "url": "https://finance.yahoo.com/news/amarin-amrn-outperforming-other-medical-134004813.html", "title": "Is Amarin (AMRN) Outperforming Other Medical Stocks This Year?", "summary": "Here is how Amarin (AMRN) and Bayer Aktiengesellschaft (BAYRY) have performed compared to their sector so far this year.", "published_at": "2025-08-06T13:40:04Z", "sentiment": "negative", "confidence": 0.9997}
{"id": "18f31dbc-0aaa-30ab-84a0-5615fa5db118", "ticker": "BAYN.DE", "url": "https://sg.finance.yahoo.com/news/indias-bayer-cropscience-posts-higher-092636222.html", "title": "India's Bayer CropScience posts higher quarterly profit on strong herbicide, corn seed demand", "summary": "Agricultural chemicals maker Bayer CropScience posted a 9.6% rise in first-quarter profit on Wednesday, backed by strong demand for its herbicide 'Roundup' and corn seeds. The Indian unit of German drugs and pesticides maker Bayer AG posted a profit of 2.79 million rupees ($31,834.8) for the three months ended June 30, compared with 2.54 billion rupees a year earlier. Revenue from operations grew 17.4% to 19.15 billion rupees.", "published_at": "2025-08-06T09:26:36Z", "sentiment": "neutral", "confidence": 1.0}
{"id": "27c409ea-993f-3d04-9142-9526f8144f3c", "ticker": "BAYN.DE", "url": "https://finance.yahoo.com/news/bayer-says-cut-12-000-055342092.html", "title": "Bayer investors concerned soccer transfers inflated earnings, shares drop", "summary": "FRANKFURT (Reuters) -Investor concerns that Bayer's earnings were inflated by soccer player transfer fees rather than supported by its core healthcare and agriculture businesses helped send its shares plummeting nearly 5% to a one-month low on Wednesday.  The German maker of pharmaceuticals and crop protection products reported in unscheduled preliminary results last week that second-quarter operating income, adjusted for some items, came in at a better-than-expected 2.1 billion euros ($2.43 billion).  In a more detailed disclosure on Wednesday, however, it said those results included higher revenue from its German Bundesliga team Bayer Leverkusen resulting from player transfers.", "published_at": "2025-08-06T05:53:42Z", "sentiment": "neutral", "confidence": 1.0}
{"id": "eecefc15-529e-3440-9309-7c93ddba2116", "ticker": "BAYN.DE", "url": "https://finance.yahoo.com/news/krys-q2-earnings-sales-top-125900208.html", "title": "KRYS Q2 Earnings and Sales Top Estimates, Stock Down on Q3 Outlook", "summary": "Krystal Biotech tops Q2 estimates with strong Vyjuvek sales, but shares fall 14% on weak Q3 revenue guidance.", "published_at": "2025-08-05T12:59:00Z", "sentiment": "neutral", "confidence": 1.0}
{"id": "27940eab-ec7f-34b8-8b00-477f2432219d", "ticker": "BAYN.DE", "url": "https://finance.yahoo.com/news/recursion-pharmaceuticals-report-q2-earnings-162300336.html", "title": "Recursion Pharmaceuticals to Report Q2 Earnings: What's in the Cards?", "summary": "RXRX eyes Q2 earnings beat despite past misses, with a refocused pipeline and new data updates on key drug candidates.", "published_at": "2025-08-04T16:23:00Z", "sentiment": "neutral", "confidence": 1.0}
{"id": "68624f44-654d-35d0-b2e0-1f9b07057d59", "ticker": "BAYN.DE", "url": "https://finance.yahoo.com/news/regeneron-stock-rises-q2-earnings-151000087.html", "title": "Regeneron Stock Rises on Q2 Earnings and Sales Beat, Eylea HD Sales Up", "summary": "REGN stock up as Q2 EPS jumps 12% on strong Eylea HD and Dupixent profits, beating revenue and earnings estimates.", "published_at": "2025-08-01T15:10:00Z", "sentiment": "neutral", "confidence": 1.0}
{"id": "e0621565-1da2-38c4-953e-4a78041d5dc2", "ticker": "BAYN.DE", "url": "https://finance.yahoo.com/news/bayer-sets-aside-more-cash-090014084.html", "title": "Bayer sets aside more cash to deal with weedkiller woes", "summary": "German pharmaceutical and agricultural chemicals giant Bayer said it had put aside an extra 1.2 billion euros ($1.4 billion) to deal with long-running US legal woes linked to a weedkiller. Despite the extra provision for the legal cases, Bayer hiked its forecasts for 2025 due to a better-than-expected performance in its pharmaceuticals division.", "published_at": "2025-08-01T12:42:27Z", "sentiment": "neutral", "confidence": 1.0}
{"id": "30629176-3e39-356c-9325-143d5ead45c7", "ticker": "BAYN.DE", "url": "https://ca.finance.yahoo.com/news/regeneron-beats-second-quarter-results-122151679.html", "title": "Regeneron posts better-than-expected Q2 results, downplays tariff impact", "summary": "(Reuters) -Regeneron topped Wall Street estimates for second-quarter results on Friday, on robust demand for its blockbuster eczema drug Dupixent, and said it does not expect a material impact from tariffs on imports from the European Union.  As the company gains clarity on details of the agreement and other potential tariffs, CEO Leonard Schleifer said the 15% duties were not expected to have a material impact.  Investors have set a high bar for Regeneron and French partner Sanofi's Dupixent, one of the U.S. drugmaker's growth drivers.", "published_at": "2025-08-01T12:21:51Z", "sentiment": "neutral", "confidence": 1.0}
{"id": "ffba2f1d-2e3b-3dae-ac7c-cb0a63c770f6", "ticker": "BAYN.DE", "url": "https://www.wsj.com/business/earnings/bayer-ups-guidance-after-pharmaceuticals-unit-outperforms-3a2876fb?siteid=yhoof2&yptr=yahoo", "title": "Bayer Ups Guidance After Pharmaceuticals Unit Outperforms", "summary": "The German pharmaceutical and agricultural conglomerate said it now expects to post revenue of more than $52.51 billion for the year.", "published_at": "2025-07-31T21:55:00Z", "sentiment": "neutral", "confidence": 0.9999}
{"id": "20a3d91e-e246-3379-9f19-2dc9ff800607", "ticker": "BAYN.DE", "url": "https://finance.yahoo.com/news/incys-q2-earnings-revenues-beat-154500772.html", "title": "INCY's Q2 Earnings & Revenues Beat Estimates on Higher Product Sales", "summary": "Incyte reports better-than-expected second-quarter 2025 results, beating both earnings and revenue estimates, driven by strong Jakafi and Opzelura sales.", "published_at": "2025-07-29T15:45:00Z", "sentiment": "neutral", "confidence": 1.0}
{"id": "1d1c968a-9c56-3232-a9ed-342032b5489d", "ticker": "BAYN.DE", "url": "https://finance.yahoo.com/news/q2-reports-shape-more-uncertain-205900426.html", "title": "Do Q2 Reports Shape a More Uncertain Outlook?", "summary": "Q4 is when major tariff effects should hit, in a macro material way.", "published_at": "2025-07-24T20:59:00Z", "sentiment": "positive", "confidence": 0.9959}
{"id": "85056535-1e9f-3459-ab49-13b33f767c9f", "ticker": "BAYN.DE", "url": "https://finance.yahoo.com/news/srpt-slides-voluntary-us-elevidys-133300953.html", "title": "SRPT Slides on Voluntary US Elevidys Shipment Pause Amid Scrutiny", "summary": "Sarepta stock down as it halts U.S. Elevidys shipments after FDA pressure and safety concerns tied to patient deaths due to liver failure.", "published_at": "2025-07-22T13:33:00Z", "sentiment": "positive", "confidence": 1.0}
{"id": "e558979e-cd9f-3b5e-99ad-e596eb1b3a51", "ticker": "BAYN.DE", "url": "https://finance.yahoo.com/news/best-value-stocks-buy-july-125800249.html", "title": "Best Value Stocks to Buy for July 22nd", "summary": "OPRT, BAYRY and SHG made it to the Zacks Rank #1 (Strong Buy) value stocks list on July 22, 2025.", "published_at": "2025-07-22T12:58:00Z", "sentiment": "neutral", "confidence": 0.9476}
{"id": "16f697c8-04d3-3d24-9436-b882d486687f", "ticker": "BAYN.DE", "url": "https://finance.yahoo.com/news/strong-buy-stocks-july-22nd-100900927.html", "title": "New Strong Buy Stocks for July 22nd", "summary": "BTG, PGR, BAYRY, BCH and LNW have been added to the Zacks Rank #1 (Strong Buy) List on July 22, 2025.", "published_at": "2025-07-22T10:09:00Z", "sentiment": "neutral", "confidence": 1.0}
{"id": "70c4dd63-188a-34f8-91dc-058c01b696ab", "ticker": "BAYN.DE", "url": "https://finance.yahoo.com/news/srpt-down-third-death-muscular-151600941.html", "title": "SRPT Down After Third Death in Muscular Dystrophy Gene Therapy Program", "summary": "Sarepta plummets after a third death in its muscular dystrophy program for investigational gene therapies, prompts FDA action and intensifies safety scrutiny.", "published_at": "2025-07-21T15:16:00Z", "sentiment": "negative", "confidence": 0.9394}
{"id": "8731f90c-c6b8-39d2-9c97-d09bec79b641", "ticker": "BAYN.DE", "url": "https://finance.yahoo.com/news/vtrs-down-stage-study-failure-134800103.html", "title": "VTRS Down on Late-Stage Study Failure of Eye Disease Drug", "summary": "VTRS slides after phase III trial failure for blepharitis drug MR-139, adding pressure to an already struggling stock.", "published_at": "2025-07-21T13:48:00Z", "sentiment": "positive", "confidence": 1.0}
{"id": "7f3632fd-6139-321a-8863-67d8e42f3815", "ticker": "BAYN.DE", "url": "https://finance.yahoo.com/news/regeneron-stock-plunges-22-6-135200864.html", "title": "Regeneron Stock Plunges 22.6% YTD: Should You Buy, Sell or Hold?", "summary": "Eylea's sales slump and pipeline setbacks have dragged REGN down 22.8% YTD, underperforming its peers and the S&P 500.", "published_at": "2025-07-18T13:52:00Z", "sentiment": "positive", "confidence": 1.0}
{"id": "0ade54ff-c9a7-3e89-80df-1cccbc66d392", "ticker": "BAYN.DE", "url": "https://finance.yahoo.com/news/regeneron-beats-second-quarter-results-122151150.html", "title": "Regeneron posts better-than-expected Q2 results, downplays tariff impact", "summary": "(Reuters) -Regeneron topped Wall Street estimates for second-quarter results on Friday, on robust demand for its blockbuster eczema drug Dupixent, and said it does not expect a material impact from tariffs on imports from the European Union.  As the company gains clarity on details of the agreement and other potential tariffs, CEO Leonard Schleifer said the 15% duties were not expected to have a material impact.  Investors have set a high bar for Regeneron and French partner Sanofi's Dupixent, one of the U.S. drugmaker's growth drivers.", "published_at": "2025-08-01T12:21:51Z", "sentiment": "neutral", "confidence": 1.0}
{"id": "f6767130-9a40-3227-a022-196cc4945585", "ticker": "BAYN.DE", "url": "https://finance.yahoo.com/news/mdgl-stock-soars-11-patent-153400777.html", "title": "MDGL Stock Soars 11% on New Patent Protecting Rezdiffra Dosing Rights", "summary": "Madrigal Pharmaceuticals stock jumps 11% after securing a new U.S. patent for Rezdiffra's dosing, reinforcing exclusivity through 2044.", "published_at": "2025-07-17T15:34:00Z", "sentiment": "neutral", "confidence": 1.0}
{"id": "358bd82d-ad0d-35d5-9f49-58f0524d9e0b", "ticker": "BAYN.DE", "url": "https://finance.yahoo.com/news/recursion-pharmaceuticals-rises-6-month-153000587.html", "title": "Recursion Pharmaceuticals Rises 6% in a Month: How to Play the Stock", "summary": "RXRX gains 5.5% in a month on positive pipeline update; long-term hold advised given strong potential of its AI-driven drug discovery platform.", "published_at": "2025-07-17T15:30:00Z", "sentiment": "neutral", "confidence": 1.0}
{"id": "8564e1b6-50c0-3437-8e9f-821e95f374a1", "ticker": "BAYN.DE", "url": "https://finance.yahoo.com/news/novartis-beats-q2-earnings-sales-134000826.html", "title": "Novartis Beats on Q2 Earnings and Sales, CFO Retires, Stock Down", "summary": "NVS beats on Q2 earnings, raises 2025 income outlook on strong drug sales, but Cosentyx miss and CFO exit weigh on shares.", "published_at": "2025-07-17T13:40:00Z", "sentiment": "neutral", "confidence": 1.0}
{"id": "ff1147fc-191d-3de6-9b70-493edde2b808", "ticker": "BAYN.DE", "url": "https://www.wsj.com/business/bayer-ceo-to-stay-at-helm-until-march-2029-a51e1abd?siteid=yhoof2&yptr=yahoo", "title": "Bayer Extends CEO’s Contract Through 2029", "summary": "Bill Anderson will stay at the helm of the pharmaceutical company until March 2029, after the supervisory board extended his contract by a further three years.", "published_at": "2025-07-16T17:52:00Z", "sentiment": "negative", "confidence": 0.9998}
{"id": "1bc7d91f-7ca6-31c9-b1ac-3afcc0d52178", "ticker": "BAYN.DE", "url": "https://finance.yahoo.com/news/recursion-pharmaceuticals-strategic-deals-fuel-135800630.html", "title": "Can Recursion Pharmaceuticals' Strategic Deals Fuel Long-Term Growth?", "summary": "RXRX is scaling its AI-driven drug discovery technology through billion-dollar pharma deals and strategic tech alliances.", "published_at": "2025-07-16T13:58:00Z", "sentiment": "neutral", "confidence": 1.0}
{"id": "7c1aa61e-682e-37ca-832e-bb51893ad815", "ticker": "BAYN.DE", "url": "https://finance.yahoo.com/news/bayry-skyrockets-62-9-ytd-122200041.html", "title": "BAYRY Skyrockets 62.9% YTD: Should You Buy or Sell the Stock?", "summary": "Bayer's shares are up 62.9% YTD as new drug approvals and a streamlined model fuel a sharp pharma turnaround.", "published_at": "2025-07-16T12:22:00Z", "sentiment": "neutral", "confidence": 1.0}
{"id": "a6c83fdb-eee4-4010-9c4a-d7216557ee51", "ticker": "BAYN.DE", "url": "https://finance.yahoo.com/news/connecticut-wants-to-make-generic-glp-1s-will-rfk-jr-lend-a-hand-145659446.html", "title": "Connecticut wants to make generic GLP-1s. Will RFK Jr. lend a hand?", "summary": "Connecticut is petitioning HHS to ignore GLP-1 patents and allow the state to manufacture generics.", "published_at": "2025-07-15T14:56:59Z", "sentiment": "negative", "confidence": 0.9975}
{"id": "62afa864-6dc1-3bf3-8193-7f5a007c5bb8", "ticker": "BAYN.DE", "url": "https://finance.yahoo.com/news/key-drugs-maintain-momentum-novartis-135000892.html", "title": "Will Key Drugs Maintain Momentum for Novartis in Q2 Earnings?", "summary": "Strong sales of Entresto, Kisqali, Kesimpta, Leqvio and Scemblix have likely benefited NVS' Q2 performance and offset the impact of generics.", "published_at": "2025-07-15T13:50:00Z", "sentiment": "neutral", "confidence": 1.0}
{"id": "d3f55af9-e3be-310d-afc8-351f5aebc462", "ticker": "BAYN.DE", "url": "https://finance.yahoo.com/news/astrazeneca-meets-key-goals-phase-123200148.html", "title": "AstraZeneca Meets All Key Goals in Phase III Hypertension Study", "summary": "AZN hits all endpoints in phase III study for baxdrostat, a first-in-class treatment targeting hard-to-manage hypertension.", "published_at": "2025-07-15T12:32:00Z", "sentiment": "negative", "confidence": 0.7992}
{"id": "375f88ca-3522-30fc-8957-c858e4817e26", "ticker": "BAYN.DE", "url": "https://finance.yahoo.com/news/ultragenyx-pharmaceuticals-gets-crl-ux111-122800750.html", "title": "Ultragenyx Pharmaceuticals Gets CRL for UX111 Gene Therapy for MPS IIIA", "summary": "RARE faces regulatory setback as FDA issues a CRL for UX111, delaying approval of the MPS IIIA gene therapy until 2026.", "published_at": "2025-07-15T12:28:00Z", "sentiment": "positive", "confidence": 0.9998}
{"id": "fa6d7bec-41f4-3764-a758-2e56ed5cfa94", "ticker": "BAYN.DE", "url": "https://finance.yahoo.com/news/bayer-gets-fda-nod-label-133200858.html", "title": "Bayer Gets FDA Nod for Label Expansion of Kerendia in Heart Failure", "summary": "BAYRY wins FDA nod to expand Kerendia's label, making it the only approved non-steroidal MR antagonist for two major conditions.", "published_at": "2025-07-14T13:32:00Z", "sentiment": "negative", "confidence": 0.999}
{"id": "52a063fd-b7b1-3a15-8a85-cf6a130d9a7c", "ticker": "BAYN.DE", "url": "https://finance.yahoo.com/news/mrus-stock-soars-30-3-144100066.html", "title": "MRUS Stock Soars 30% in 3 Months After Phase II Cancer Study Success", "summary": "Merus jumps 30% in three months after its cancer combo therapy showed significant efficacy in a phase II head and neck squamous cell carcinoma study.", "published_at": "2025-07-11T14:41:00Z", "sentiment": "neutral", "confidence": 0.9935}
{"id": "18457246-f235-3ade-8637-0d9480ed87f0", "ticker": "BAYN.DE", "url": "https://finance.yahoo.com/news/bayer-wins-hormone-free-treatment-141000874.html", "title": "Bayer Wins Hormone-Free Treatment Approval for Women in the UK", "summary": "BAYRY secures first global approval for Lynkuet in the UK, a hormone-free treatment for menopause-related hot flashes.", "published_at": "2025-07-11T14:10:00Z", "sentiment": "neutral", "confidence": 0.9949}
{"id": "c28defc3-2719-3210-bfc3-b839733952b9", "ticker": "BAYN.DE", "url": "https://finance.yahoo.com/news/rare-mreo-fall-osteogenesis-study-141700542.html", "title": "RARE, MREO Fall as Osteogenesis Study Likely to Continue Till Year End", "summary": "Ultragenyx Pharmaceutical and Mereo BioPharma shares tumble as investors await key phase III UX143 osteogenesis data now set for release at year-end.", "published_at": "2025-07-10T14:17:00Z", "sentiment": "positive", "confidence": 0.9998}
{"id": "8c6ff3a0-a484-3c3d-b177-f35fa37ef490", "ticker": "BAYN.DE", "url": "https://finance.yahoo.com/news/best-value-stocks-buy-july-115400658.html", "title": "Best Value Stocks to Buy for July 10th", "summary": "BAYRY, INSW and GOOS made it to the Zacks Rank #1 (Strong Buy) value stocks list on July 10, 2025.", "published_at": "2025-07-10T11:54:00Z", "sentiment": "neutral", "confidence": 0.926}
{"id": "8720e41b-ffcc-31ee-bca7-a099b39433fc", "ticker": "BAYN.DE", "url": "https://finance.yahoo.com/news/strong-buy-stocks-july-10th-093500571.html", "title": "New Strong Buy Stocks for July 10th", "summary": "ASTH, LGCY, STM, BAYRY and KD have been added to the Zacks Rank #1 (Strong Buy) List on July 10, 2025.", "published_at": "2025-07-10T09:35:00Z", "sentiment": "neutral", "confidence": 1.0}
{"id": "97de1f2a-36c9-33a1-9fa9-64699fb2dbe7", "ticker": "BAYN.DE", "url": "https://finance.yahoo.com/news/rxrx-stock-acquiring-full-rights-155600011.html", "title": "RXRX Stock Up on Acquiring Full Rights to the Hypophosphatasia Program", "summary": "Recursion Pharmaceuticals stock jumps after securing full rights to REV102, aiming to fast-track the first oral therapy for hypophosphatasia.", "published_at": "2025-07-09T15:56:00Z", "sentiment": "neutral", "confidence": 0.6832}
{"id": "d86f38bc-79a5-3a97-8871-ff7c36c87ff5", "ticker": "BAYN.DE", "url": "https://www.wsj.com/livecoverage/stock-market-today-dow-sp-500-nasdaq-07-09-2025/card/trump-s-drug-tariffs-where-does-the-u-s-import-pharmaceuticals-from--VxcNmYWBgmbSL4r4gqQF?siteid=yhoof2&yptr=yahoo", "title": "Trump's Drug Tariffs: Where Does the U.S. Import Pharmaceuticals From?", "summary": "President Trump has threatened to slap a 200% tariff on foreign-made pharmaceuticals. That would roil the $200 billion-plus market for drug imports. Here's a breakdown of which countries—and medicines—could be exposed.", "published_at": "2025-07-09T11:29:40Z", "sentiment": "negative", "confidence": 0.9965}
{"id": "9891cb61-c26e-3c8a-9e46-f5b2598adfc8", "ticker": "BAYN.DE", "url": "https://finance.yahoo.com/news/cogt-stock-soars-phase-iii-145400775.html", "title": "COGT Stock Soars on Phase III Systemic Mastocytosis Study Success", "summary": "Cogent Biosciences stock jumps 23.4% after bezuclastinib hits primary and all key secondary endpoints in a phase III systemic mastocytosis study.", "published_at": "2025-07-08T14:54:00Z", "sentiment": "negative", "confidence": 0.6098}
{"id": "5d809431-ab41-3504-b77b-4f1d3f070143", "ticker": "BAYN.DE", "url": "https://finance.yahoo.com/news/mbio-soars-orphan-drug-nod-143800535.html", "title": "MBIO Soars on Orphan Drug Nod for Investigational Brain Cancer Therapy", "summary": "Mustang Bio surges 180% after its brain cancer therapy, MB-101, earns FDA Orphan Drug status for two rare brain tumor types.", "published_at": "2025-07-08T14:38:00Z", "sentiment": "negative", "confidence": 0.9882}
{"id": "9a59a5ed-af3d-39dc-8f95-b9b569aaba0c", "ticker": "BAYN.DE", "url": "https://finance.yahoo.com/news/bayer-begins-phase-ii-study-143100275.html", "title": "Bayer Begins Phase I/II Study on Cell Therapy for Eye Disease", "summary": "BAYRY begins human trials for OpCT-001, an experimental cell therapy for treating primary photoreceptor diseases.", "published_at": "2025-07-08T14:31:00Z", "sentiment": "negative", "confidence": 1.0}
{"id": "96583d97-ce79-3551-96c7-7492ac06c60f", "ticker": "BAYN.DE", "url": "https://finance.yahoo.com/news/top-stock-reports-mastercard-cisco-204100396.html", "title": "Top Stock Reports for Mastercard, Cisco & TJX", "summary": "MA, CSCO and TJX are leveraging digital adoption, recurring revenues, and value-driven retail to outpace their industries.", "published_at": "2025-07-07T20:41:00Z", "sentiment": "neutral", "confidence": 1.0}
{"id": "04aa7271-742c-3706-b2d9-97f1c73bfe85", "ticker": "BAYN.DE", "url": "https://finance.yahoo.com/news/makes-bayer-bayry-buy-stock-160002904.html", "title": "What Makes Bayer (BAYRY) a New Buy Stock", "summary": "Bayer (BAYRY) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).", "published_at": "2025-07-03T16:00:02Z", "sentiment": "neutral", "confidence": 1.0}
{"id": "45717e82-2a51-346f-a250-507cbfd63065", "ticker": "BAYN.DE", "url": "https://finance.yahoo.com/news/novartis-cosentyx-misses-primary-goal-143200013.html", "title": "Novartis' Cosentyx Misses Primary Goal in Arteritis Phase III Study", "summary": "NVS' Cosentyx fails to meet its primary goal in a phase III study for giant cell arteritis, despite favorable safety data.", "published_at": "2025-07-03T14:32:00Z", "sentiment": "positive", "confidence": 1.0}
{"id": "6d06c75d-c413-3f33-8cc1-b19ff19ec963", "ticker": "BAYN.DE", "url": "https://finance.yahoo.com/news/dexcom-dxcm-stock-outpacing-medical-134003027.html", "title": "Is DexCom (DXCM) Stock Outpacing Its Medical Peers This Year?", "summary": "Here is how DexCom (DXCM) and Bayer Aktiengesellschaft (BAYRY) have performed compared to their sector so far this year.", "published_at": "2025-07-03T13:40:03Z", "sentiment": "negative", "confidence": 0.9991}
{"id": "55c103b6-7dd5-3b58-afb4-8cde256c69ae", "ticker": "BAYN.DE", "url": "https://finance.yahoo.com/news/fda-grants-accelerated-approval-regenerons-131600163.html", "title": "FDA Grants Accelerated Approval to Regeneron's Blood Cancer Drug", "summary": "REGN scores FDA approval for Lynozyfic in tough-to-treat multiple myeloma, bolstering its oncology pipeline amid Eylea headwinds.", "published_at": "2025-07-03T13:16:00Z", "sentiment": "neutral", "confidence": 1.0}
{"id": "3da2c5b8-d8e6-3dcc-a5b7-c5bf3ee5a18a", "ticker": "BAYN.DE", "url": "https://www.euronews.com/health/2025/07/02/eu-pharma-chief-calls-for-european-nasdaq-to-boost-biotech-innovation?utm_source=yahoo&utm_campaign=feeds_business_articles_2024&utm_medium=referral", "title": "EU pharma chief calls for European Nasdaq to boost biotech innovation", "summary": "The head of the EU's pharmaceutical lobby has called for the creation of a life sciences-focused stock market in Europe, modelled after the US Nasdaq, to help retain biotech innovation and investment within the region.View on euronews", "published_at": "2025-07-02T12:47:36Z", "sentiment": "neutral", "confidence": 0.9996}
{"id": "4e6315cf-3335-3781-aec5-df92e3206258", "ticker": "BAYN.DE", "url": "https://finance.yahoo.com/news/rares-gtx-102-gets-fdas-154000797.html", "title": "RARE's GTX-102 Gets FDA's Breakthrough Status for Angelman Syndrome", "summary": "Ultragenyx Pharmaceuticals' GTX-102 earns FDA Breakthrough status after early data shows sustained progress in Angelman syndrome patients.", "published_at": "2025-06-30T15:40:00Z", "sentiment": "neutral", "confidence": 1.0}
{"id": "85bdacb6-2165-3ff3-84f9-1cec20aaabac", "ticker": "BAYN.DE", "url": "https://finance.yahoo.com/news/krys-4-initiating-dosing-rare-151700102.html", "title": "KRYS Up 4% on Initiating Dosing in Rare Eye Disease Phase III Study", "summary": "Krystal Biotech rises 4% after dosing begins in a phase III study of KB803 eye drops to treat rare DEB-related corneal damage.", "published_at": "2025-06-25T15:17:00Z", "sentiment": "negative", "confidence": 0.9987}
{"id": "65bf0ffa-368a-3b2d-b4c5-f28f20210b9c", "ticker": "BAYN.DE", "url": "https://finance.yahoo.com/news/amarin-soars-27-vazkepa-licensing-150600766.html", "title": "Amarin Soars 27% on Vazkepa Licensing Deal With Recordati in the EU", "summary": "AMRN jumps 27% after inking an exclusive EU licensing deal with Recordati to expand Vazkepa's reach and cut costs.", "published_at": "2025-06-25T15:06:00Z", "sentiment": "neutral", "confidence": 1.0}
{"id": "d83cc87c-f2b6-358f-b6c5-f3bc28b7261b", "ticker": "BAYN.DE", "url": "https://finance.yahoo.com/news/chmp-backs-nvos-ozempic-eu-155800216.html", "title": "CHMP Backs NVO's Ozempic EU Label Update for Cardiovascular Indication", "summary": "CHMP recommends a label update for Novo Nordisk's Ozempic after the STRIDE study shows walking improvements in T2D patients with PAD.", "published_at": "2025-06-24T15:58:00Z", "sentiment": "negative", "confidence": 0.9971}
{"id": "53411282-39f9-3da0-92b8-95627dfdb6d8", "ticker": "BAYN.DE", "url": "https://www.investors.com/news/technology/exelixis-stock-next-generation-cancer-drug-colon-cancer/?src=A00220&yptr=yahoo", "title": "Exelixis Surges On Positive Results For Next-Gen Colon Cancer Drug", "summary": "Exelixis stock surged Monday after the company said its next-generation cancer drug showed promise in a colon cancer study.", "published_at": "2025-06-23T20:27:05Z", "sentiment": "neutral", "confidence": 1.0}
{"id": "d232c0a5-7f6e-386d-bb28-ae481c4898ba", "ticker": "BAYN.DE", "url": "https://finance.yahoo.com/news/fda-extends-incys-application-opzelura-135300321.html", "title": "FDA Extends INCY's Application for Opzelura Label Expansion", "summary": "FDA extends review of Incyte's ruxolitinib cream for children with atopic dermatitis, delaying decision to September 2025.", "published_at": "2025-06-23T13:53:00Z", "sentiment": "negative", "confidence": 0.7784}
{"id": "17f898e2-c3a5-3502-82bf-8955313ad03c", "ticker": "BAYN.DE", "url": "https://finance.yahoo.com/news/fda-approves-gileads-twice-yearly-173000636.html", "title": "FDA Approves Gilead's Twice-Yearly Shot for HIV Prevention", "summary": "GILD wins FDA approval for Yeztugo, the first and only twice-yearly injectable PrEP for HIV prevention in the United States.", "published_at": "2025-06-19T17:30:00Z", "sentiment": "neutral", "confidence": 0.9992}
{"id": "6e038a65-9cf8-3939-bf91-266ab9536035", "ticker": "BAYN.DE", "url": "https://finance.yahoo.com/news/bayer-seeks-fda-approval-mri-145100140.html", "title": "Bayer Seeks FDA Approval for MRI Contrast Agent Gadoquatrane", "summary": "BAYRY files for FDA nod to gadoquatrane, a low-dose MRI contrast agent backed by strong QUANTI study results.", "published_at": "2025-06-18T14:51:00Z", "sentiment": "neutral", "confidence": 1.0}
{"id": "1d180a38-886f-37cc-8b40-6a49b46f2c5c", "ticker": "BAYN.DE", "url": "https://finance.yahoo.com/news/incyte-stock-rises-qiagen-deal-160800070.html", "title": "Incyte Stock Rises on QIAGEN Deal to Advance Blood Cancer Diagnostics", "summary": "INCY jumps 5.1% on a global QIAGEN deal to develop a companion diagnostic for its mutCALR-targeting cancer therapy.", "published_at": "2025-06-17T16:08:00Z", "sentiment": "negative", "confidence": 0.966}
{"id": "6f395137-fe0a-3828-b94a-1c0145beca65", "ticker": "BAYN.DE", "url": "https://finance.yahoo.com/news/teva-partners-fosun-develop-tev-160200038.html", "title": "Teva Partners With Fosun to Develop TEV-56278 Immuno-Cancer Therapy", "summary": "TEVA teams up with Fosun to speed the development of TEV-56278, a novel anti-cancer immunotherapy targeting PD-1+ T cells.", "published_at": "2025-06-17T16:02:00Z", "sentiment": "negative", "confidence": 0.9979}
{"id": "92916995-8ef8-3d9c-955a-d68faff0f278", "ticker": "BAYN.DE", "url": "https://finance.yahoo.com/news/5-large-drug-stocks-poised-130600327.html", "title": "5 Large Drug Stocks That Are Poised to Ride on Sector Recovery", "summary": "In the Large-Cap Pharmaceuticals industry, AbbVie, Novartis, Pfizer, Sanofi and Bayer are worth retaining amid macro pressure and rising innovation.", "published_at": "2025-06-16T13:06:00Z", "sentiment": "neutral", "confidence": 1.0}
{"id": "9760717a-4fc3-353a-a534-d00c5772b5fb", "ticker": "BAYN.DE", "url": "https://finance.yahoo.com/news/medical-stocks-lagging-amneal-pharmaceuticals-134011867.html", "title": "Are Medical Stocks Lagging  Amneal Pharmaceuticals (AMRX) This Year?", "summary": "Here is how Amneal Pharmaceuticals (AMRX) and Bayer Aktiengesellschaft (BAYRY) have performed compared to their sector so far this year.", "published_at": "2025-06-13T13:40:11Z", "sentiment": "negative", "confidence": 1.0}
{"id": "fb0111bf-e5a6-3523-a86c-4d3b89058158", "ticker": "BAYN.DE", "url": "https://finance.yahoo.com/news/goldman-sachs-upgrades-bayer-bayry-032528002.html", "title": "Goldman Sachs Upgrades Bayer (BAYRY) to Buy", "summary": "On Thursday, Goldman Sachs analyst James Quigley upgraded Bayer Aktiengesellschaft (OTC:BAYRY) to Buy from Neutral, while setting a price target of EUR 33. Quigley indicated that the stock’s risk/reward profile appears positive as it approaches H2 2025, with potential catalysts that could drive a re-rating in the medium term. This upgrade follows Bayer’s strong operational […]", "published_at": "2025-06-06T03:25:28Z", "sentiment": "neutral", "confidence": 1.0}
{"id": "bfb0f707-f0a3-3060-b123-8c15a520c0bd", "ticker": "BAYN.DE", "url": "https://finance.yahoo.com/news/airlines-must-ink-long-term-204315598.html", "title": "Airlines must ink long-term deals on greener fuels to boost volumes: Bayer exec", "summary": "MONTREAL (Reuters) -Airlines need to reach long-term agreements to buy bigger quantities of sustainable aviation fuel if they want to boost global volumes of the lower-emission fuel required for industry climate targets, a Bayer executive said on Tuesday.  Airline members of the International Air Transport Association are sticking to a target of net zero emissions by 2050 despite warnings that carriers will struggle to meet such sustainability goals due to low production of SAF, which is more expensive than conventional jet fuel.  IATA, which wrapped up a summit in India on Tuesday, expects the amount of sustainable aviation fuel produced to double in 2025 to reach 2 million tonnes, representing 0.7% of airlines' fuel consumption.", "published_at": "2025-06-03T20:43:15Z", "sentiment": "positive", "confidence": 0.9085}
{"id": "c2a664d5-4370-38be-bd63-2037b0100548", "ticker": "BAYN.DE", "url": "https://www.biopharmadive.com/news/bayer-asco-elinzanetant-vasomotor-symptoms-breast-cancer/749648/", "title": "Bayer drug could ease side effects of common breast cancer treatment, detailed data show", "summary": "Elinzanetant proved effective for managing disruptive vasomotor symptoms in women on endocrine therapy, supporting a Bayer application for approval.", "published_at": "2025-06-03T11:57:00Z", "sentiment": "neutral", "confidence": 1.0}
{"id": "05d0a5db-2909-3cb7-a367-6a02f2fed11a", "ticker": "BAYN.DE", "url": "https://finance.yahoo.com/news/oric-stock-surges-upbeat-initial-155300376.html", "title": "ORIC Stock Surges on Upbeat Initial Data From Prostate Cancer Study", "summary": "ORIC Pharmaceuticals stock rises 20% pre-market on early data showing strong PSA responses and tolerability for prostate cancer drug ORIC-944 in phase Ib study.", "published_at": "2025-05-29T15:53:00Z", "sentiment": "neutral", "confidence": 1.0}
{"id": "936bd3fb-de23-35e6-81f9-dfe26bd5854f", "ticker": "BAYN.DE", "url": "https://finance.yahoo.com/news/bayer-bayry-outperforming-other-medical-134009073.html", "title": "Is Bayer (BAYRY) Outperforming Other Medical Stocks This Year?", "summary": "Here is how Bayer Aktiengesellschaft (BAYRY) and BioCryst Pharmaceuticals (BCRX) have performed compared to their sector so far this year.", "published_at": "2025-05-28T13:40:09Z", "sentiment": "negative", "confidence": 1.0}
{"id": "821fbf72-dbed-3154-b228-33ec46ba8fd6", "ticker": "BAYN.DE", "url": "https://finance.yahoo.com/news/trump-trade-trump-considers-50-141535896.html", "title": "Trump Trade: Trump considers 50% tariff on EU, 25% on iPhones", "summary": "Catch up on the top industries and stocks that were impacted, or were predicted to be impacted, by the comments, actions and policies of President Donald Trump with this daily recap compiled by The Fly: TARIFF ON EU: President Donald Trump stated in a post to Truth Social, “The European Union, which was formed for the primary purpose of taking advantage of the United States on TRADE, has been very difficult to deal with. Their powerful Trade Barriers, Vat Taxes, ridiculous Corporate Penalties, N", "published_at": "2025-05-24T14:15:35Z", "sentiment": "positive", "confidence": 0.6635}
{"id": "6f8df575-f517-341f-99bc-2abfd7b8807e", "ticker": "BAYN.DE", "url": "https://finance.yahoo.com/news/bayer-gets-chmp-nod-eylea-140100333.html", "title": "Bayer Gets CHMP Nod for Eylea 8 mg in the EU for 2 Major Eye Diseases", "summary": "BAYRY's Eylea 8 mg gets CHMP nod in EU, promising 6-month dosing for nAMD and DME with strong 3-year efficacy and safety data.", "published_at": "2025-05-23T14:01:00Z", "sentiment": "neutral", "confidence": 1.0}
{"id": "11d22d68-702a-3e35-bfc7-b636aeca62dd", "ticker": "BAYN.DE", "url": "https://www.pharmaceutical-technology.com/news/bayer-eylea-set-for-longer-treatment-intervals-to-challenge-roches-vabysmo/", "title": "Bayer’s Eylea set for longer treatment intervals to challenge Roche’s Vabysmo", "summary": "An EMA committee has issued a positive opinion for a label extension that would allow six-month injection intervals for Eylea 8mg.", "published_at": "2025-05-23T11:39:05Z", "sentiment": "neutral", "confidence": 1.0}
{"id": "04312bd1-7192-339a-be6d-3dad4c1e5019", "ticker": "BAYN.DE", "url": "https://finance.yahoo.com/news/bayer-begins-phase-study-bay-163300213.html", "title": "Bayer Begins Phase I Study on BAY 3670549 in Atrial Fibrillation", "summary": "The phase I study evaluates BAYRY's investigational GIRK4 inhibitor, BAY 3670549, for the treatment of patients with atrial fibrillation.", "published_at": "2025-05-21T16:33:00Z", "sentiment": "negative", "confidence": 1.0}
{"id": "62b1ef38-953b-35ff-8941-1bfb05fd4bca", "ticker": "BAYN.DE", "url": "https://finance.yahoo.com/news/bayer-reports-fda-approved-jivi-153516620.html", "title": "Bayer reports FDA approved Jivi for use in pediatric patients 7 years and older", "summary": "Bayer (BAYRY) announced that the U.S. Food and Drug Administration has approved Jivi, a recombinant DNA-derived, extended half-life factor VIII concentrate, for use in pediatric patients 7 years of age and older with hemophilia A. The approval is based on data from the Alfa-PROTECT and PROTECT Kids studies, demonstrating Jivi’s safety and efficacy in children aged 7 to under 12 years with severe hemophilia A. This significant milestone reflects Bayer’s ongoing commitment to providing effective t", "published_at": "2025-05-20T15:35:16Z", "sentiment": "neutral", "confidence": 0.9998}
{"id": "02667b54-ec9c-3dd8-8011-9cb4a41d5720", "ticker": "BAYN.DE", "url": "https://finance.yahoo.com/news/zacks-analyst-blog-highlights-bayer-135100559.html", "title": "The Zacks Analyst Blog Highlights Bayer, Novo Nordisk, GSK, Merck and AbbVie", "summary": "Bayer, Novo Nordisk, GSK, Merck and AbbVie are part of the Zacks top Analyst Blog.", "published_at": "2025-05-19T13:51:00Z", "sentiment": "negative", "confidence": 1.0}
{"id": "b72c492d-c83b-3dad-a158-f26f7d28d191", "ticker": "BAYN.DE", "url": "https://finance.yahoo.com/news/dhanuka-agritech-ltd-bom-507717-070202279.html", "title": "Dhanuka Agritech Ltd (BOM:507717) Q4 2025 Earnings Call Highlights: Strong Revenue Growth and ...", "summary": "Dhanuka Agritech Ltd (BOM:507717) reports impressive revenue and EBITDA growth, while expanding its global footprint with strategic acquisitions.", "published_at": "2025-05-17T07:02:02Z", "sentiment": "neutral", "confidence": 1.0}
{"id": "67b442fa-0d54-35a9-ac1d-5bca2423a2a9", "ticker": "BAYN.DE", "url": "https://finance.yahoo.com/news/pharma-stock-roundup-bayry-q1-120600251.html", "title": "Pharma Stock Roundup: BAYRY Q1 Earnings, NVO & GSK's New Deals", "summary": "Bayer reports first-quarter results. NVO and GSK announce licensing deals with smaller biotechs.", "published_at": "2025-05-16T12:06:00Z", "sentiment": "negative", "confidence": 1.0}
{"id": "47fdda60-6d9a-392d-9e36-f41f1ae693cb", "ticker": "BAYN.DE", "url": "https://www.wsj.com/articles/bayer-seeks-new-roundup-settlement-while-exploring-monsanto-bankruptcy-35bf28de?siteid=yhoof2&yptr=yahoo", "title": "Bayer Seeks New Roundup Settlement While Exploring Monsanto Bankruptcy", "summary": "The agricultural giant is preparing to place its U.S. subsidiary Monsanto in bankruptcy if a settlement with tort plaintiffs fails.", "published_at": "2025-05-15T22:46:00Z", "sentiment": "negative", "confidence": 0.9957}
{"id": "db68ad3b-0e75-3cf5-b157-e3b653fdd41f", "ticker": "BAYN.DE", "url": "https://finance.yahoo.com/news/bayer-us-head-says-fda-221639784.html", "title": "Bayer US head says FDA chief reassured pharma executives of timely reviews", "summary": "Bayer Pharmaceuticals' chief operating officer said the head of the top U.S. drug regulator recently reassured industry executives that the Food and Drug Administration would meet its targets for reviews despite recent job cuts and a restructuring.  \"We're looking at an FDA and scientific review staff that is stable, engaged and meeting its deadlines,\" Sebastian Guth, who oversees Bayer's U.S. operations, said in an interview.  Guth said that after a recent meeting between FDA Commissioner Marty Makary and industry executives, he was confident that the leadership wanted to maintain the agency's standards.", "published_at": "2025-05-15T22:16:39Z", "sentiment": "neutral", "confidence": 0.9904}
{"id": "c45e8818-aeee-3b35-84bc-b6ff7c8d91f4", "ticker": "BAYN.DE", "url": "https://finance.yahoo.com/news/bayer-ag-bayry-q1-2025-070553092.html", "title": "Bayer AG (BAYRY) Q1 2025 Earnings Call Highlights: Navigating Challenges and Capitalizing on ...", "summary": "Bayer AG (BAYRY) demonstrates resilience with strong pharmaceutical growth and strategic advancements, despite regulatory and litigation hurdles.", "published_at": "2025-05-14T07:05:53Z", "sentiment": "neutral", "confidence": 1.0}
{"id": "eb087028-0d77-362b-8172-9d6e24966ff9", "ticker": "BAYN.DE", "url": "https://www.wsj.com/livecoverage/stock-market-cpi-inflation-tariffs-05-13-2025/card/stocks-to-watch-tuesday-coinbase-boeing-hertz-Px33NRXRTj7z3pZqwdNt?siteid=yhoof2&yptr=yahoo", "title": "Stocks to Watch Tuesday: Coinbase, Boeing, Hertz, UnitedHealth", "summary": "↗️ Coinbase (COIN): Shares surged 24% after S&P Dow Jones Indices said the crypto exchange will join the S&P 500 on May 19. ↗️ Boeing (BA): The aviation company's shares rose 2.5% after China scrapped a ban on airlines taking delivery of Boeing planes.", "published_at": "2025-05-13T20:25:07Z", "sentiment": "neutral", "confidence": 0.9999}
{"id": "7145aeab-42dc-3dfc-b2a5-7dc21f84a173", "ticker": "BAYN.DE", "url": "https://finance.yahoo.com/news/bayer-q1-earnings-beat-estimates-135600838.html", "title": "Bayer Q1 Earnings Beat Estimates, Crop Science Unit Hurts Sales", "summary": "BAYRY's first-quarter earnings beat expectations. Revenues miss estimates, mainly due to lower sales of its products in the Crop Science division.", "published_at": "2025-05-13T13:56:00Z", "sentiment": "positive", "confidence": 0.9831}
{"id": "a816eb13-6150-375e-9703-e68e3af8c3aa", "ticker": "BAYN.DE", "url": "https://finance.yahoo.com/news/georgia-become-second-us-state-154610954.html", "title": "Georgia becomes second US state to shield maker of Roundup weed killer from some cancer claims", "summary": "In a victory for global agrochemical maker Bayer, Georgia has become the second state to shield pesticide manufacturers from some lawsuits claiming that they failed to warn customers of potential dangers.  The legislation signed Friday by Georgia Gov. Brian Kemp is designed to protect Bayer from lawsuits claiming that it failed to tell customers that its popular weed killer Roundup could cause cancer.  It's written broadly enough to provide legal protection in Georgia to any pesticide manufacturer that follows federal labeling requirements.", "published_at": "2025-05-12T15:46:10Z", "sentiment": "neutral", "confidence": 0.663}
{"id": "0cfdfd46-c086-31c3-887c-a45504767ba0", "ticker": "BAYN.DE", "url": "https://finance.yahoo.com/news/medical-stocks-lagging-bayer-bayry-134009688.html", "title": "Are Medical Stocks Lagging  Bayer (BAYRY) This Year?", "summary": "Here is how Bayer Aktiengesellschaft (BAYRY) and Boston Scientific (BSX) have performed compared to their sector so far this year.", "published_at": "2025-05-12T13:40:09Z", "sentiment": "negative", "confidence": 1.0}
{"id": "d20cd55c-cbf0-33ec-a504-b65ea1b83343", "ticker": "BAYN.DE", "url": "https://finance.yahoo.com/news/bayer-exit-us-seed-treatment-231356463.html", "title": "Bayer to exit US seed treatment equipment business, email says", "summary": "Bayer is exiting the seed treatment equipment business in the United States to help the company's finances, according to an email sent to customers that was seen by Reuters on Wednesday.  A spokesperson confirmed that Bayer was exiting the business, which manufactured equipment involved in the process of treating farm seeds with products like fungicides and insecticides before planting in efforts to protect crop yields.  It added that Bayer decided to direct resources toward primary areas of strength in crop protection products.", "published_at": "2025-04-30T23:13:56Z", "sentiment": "negative", "confidence": 0.9833}
{"id": "46115cd1-0f7e-308a-8e8f-5df8a81f5c4f", "ticker": "BAYN.DE", "url": "https://finance.yahoo.com/news/regeneron-stock-falls-q1-earnings-172200060.html", "title": "Regeneron Stock Falls on Q1 Earnings and Sales Miss, Eylea Sales Down", "summary": "REGN reports lower-than-expected Q1 results. Lead drug Eylea sales plunge in the United States due to competition. Stock down.", "published_at": "2025-04-29T17:22:00Z", "sentiment": "positive", "confidence": 1.0}
{"id": "eed984fa-103c-3b6f-993a-b6eacca94393", "ticker": "BAYN.DE", "url": "https://finance.yahoo.com/news/north-dakota-enacts-nations-first-201852922.html", "title": "North Dakota enacts nation's first law shielding Roundup's maker from some cancer lawsuits", "summary": "A new first-of-its-kind law enacted in North Dakota could shield agrochemical manufacturer Bayer from lawsuits claiming it failed to warn customers that its popular weedkiller Roundup could cause cancer.  The next state to follow North Dakota could be Georgia, where a similar bill is pending before Gov. Brian Kemp.  Bayer, based in Germany, acquired Roundup with the 2018 purchase of St. Louis-based Monsanto.", "published_at": "2025-04-24T20:18:52Z", "sentiment": "negative", "confidence": 0.9852}
{"id": "15550b3d-4b52-3b3c-af76-80a6839b8e1a", "ticker": "BAYN.DE", "url": "https://finance.yahoo.com/news/world-bank-adds-bayer-hyatt-170405873.html", "title": "World Bank adds Bayer, Hyatt and other CEOs to private sector initiative", "summary": "WASHINGTON (Reuters) -The World Bank on Wednesday added four top executives, including Bayer AG CEO Bill Anderson and Hyatt Hotels CEO Mark Hoplamazian, to an initiative working to address barriers to private sector investment in developing countries.  World Bank President Ajay Banga, former CEO of Mastercard, launched the Private Sector Investment Lab shortly after taking office in June 2023, assembling 15 business leaders to brainstorm ways to create more jobs in developing countries.", "published_at": "2025-04-23T17:04:05Z", "sentiment": "negative", "confidence": 0.9944}
{"id": "c5a689f7-9049-3ec0-bd2c-9b79399b64f8", "ticker": "BAYN.DE", "url": "https://www.pharmaceutical-technology.com/news/concertai-bayer-oncology/", "title": "ConcertAI and Bayer to boost precision oncology with AI and ML insights", "summary": "Translational360 is a recently introduced integrated research-grade longitudinal clinical molecular database.", "published_at": "2025-04-23T11:04:44Z", "sentiment": "neutral", "confidence": 0.9656}
{"id": "192ccb18-940d-3d66-af17-e18c33ad72df", "ticker": "BAYN.DE", "url": "https://finance.yahoo.com/news/bayer-obtains-full-fda-approval-171800211.html", "title": "Bayer Obtains Full FDA Approval for Oncology Drug Vitrakvi", "summary": "The FDA converts its accelerated approval to full approval for BAYRY's oncology drug, Vitrakvi, on positive data from confirmatory studies.", "published_at": "2025-04-11T17:18:00Z", "sentiment": "neutral", "confidence": 1.0}
{"id": "418376ef-1e06-3487-9917-950372855e4b", "ticker": "BAYN.DE", "url": "https://finance.yahoo.com/news/fda-grants-complete-approval-bayers-210219806.html", "title": "FDA Grants Complete Approval To Bayer's Drug For Certain Type Cancer With Mutation", "summary": "The U.S. Food And Drug Administration (FDA) granted full approval to Bayer AG’s (OTC:BAYRY) Vitrakvi (larotrectinib) for adult and pediatric patients with solid tumors that have a neurotrophic receptor tyrosine kinase (NTRK) gene fusion. Vitrakvi has demonstrated clinically meaningful and durable responses across various NTRK fusion-positive solid tumors. FDA first granted Vitrakvi accelerated approval in November 2018. The approval is based on data from three multicenter, open-label, single-arm", "published_at": "2025-04-10T21:02:19Z", "sentiment": "neutral", "confidence": 0.9997}
{"id": "f5bf9fba-4e04-4586-9229-a79559745695", "ticker": "BAYN.DE", "url": "https://uk.finance.yahoo.com/news/tsmc-trump-media-us-steel-novo-nordisk-tesco-trending-tickers-094532440.html", "title": "Trending tickers: TSMC, Trump Media, US Steel, Novo Nordisk and Tesco", "summary": "The latest investor updates on stocks that are trending on Thursday.", "published_at": "2025-04-10T09:45:32Z", "sentiment": "negative", "confidence": 1.0}
{"id": "11698a51-725b-4821-a4b0-4a131cc5bafe", "ticker": "BAYN.DE", "url": "https://uk.finance.yahoo.com/news/apple-advanced-micro-devices-ford-bp-astrazeneca-trending-tickers-093254195.html", "title": "Trending tickers: Apple, Advanced Micro Devices, Ford, BP and AstraZeneca", "summary": "The latest investor updates on stocks that are trending on Wednesday.", "published_at": "2025-04-09T09:32:54Z", "sentiment": "negative", "confidence": 1.0}
{"id": "4c8e6d1e-ac74-3c53-8208-60f7b3c587cc", "ticker": "BAYN.DE", "url": "https://finance.yahoo.com/news/bayers-vividion-initiates-dosing-early-174500067.html", "title": "Bayer's Vividion Initiates Dosing in Early-Stage Cancer Study", "summary": "BAYRY subsidiary Vividion Therapeutics doses the first patient in a phase I study on VVD-159642 to treat advanced solid tumors.", "published_at": "2025-04-04T17:45:00Z", "sentiment": "negative", "confidence": 0.9999}
{"id": "68762009-184b-3e69-97c5-b9948dad4603", "ticker": "BAYN.DE", "url": "https://finance.yahoo.com/news/j-js-third-bankruptcy-attempt-133000946.html", "title": "J&J's Third Bankruptcy Attempt to End Talc Suits Rejected", "summary": "J&J fails in its third attempt to settle tens of thousands of lawsuits claiming its talc-based powder caused cancer.", "published_at": "2025-04-01T13:30:00Z", "sentiment": "negative", "confidence": 0.9862}
{"id": "5f8d1c19-9731-33ec-b3db-8fbb8ed96869", "ticker": "BAYN.DE", "url": "https://finance.yahoo.com/news/bayer-licenses-prmt5-inhibitor-suzhou-163700910.html", "title": "Bayer Licenses PRMT5 inhibitor From Suzhou Puhe BioPharma", "summary": "Bayer obtains an exclusive worldwide license for MTA-cooperative PRMT5 inhibitor from Suzhou Puhe BioPharma for selective targeting of MTAP-deleted tumors.", "published_at": "2025-03-27T16:37:00Z", "sentiment": "negative", "confidence": 0.9986}
{"id": "00769bcd-00a1-3277-8b95-f316cfcc1a71", "ticker": "BAYN.DE", "url": "https://finance.yahoo.com/news/bayer-bayry-forms-hammer-chart-135502191.html", "title": "Bayer (BAYRY) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?", "summary": "Bayer (BAYRY) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.", "published_at": "2025-03-26T13:55:02Z", "sentiment": "neutral", "confidence": 1.0}
{"id": "60c9ac9b-321b-380c-a028-17e0cda9593b", "ticker": "BAYN.DE", "url": "https://finance.yahoo.com/news/bayer-down-verdict-pay-2-190000754.html", "title": "Bayer Down on Verdict to Pay $2.1B to Plaintiff in Roundup Litigation", "summary": "BAYRY suffers a setback after the jury at the Barnes Roundup trial in the State Court of Cobb County, Georgia, reached a verdict in favor of the plaintiff. Stock declines.", "published_at": "2025-03-25T19:00:00Z", "sentiment": "positive", "confidence": 0.9989}
{"id": "15411ead-6683-3ed7-87b7-1f62545995ec", "ticker": "BAYN.DE", "url": "https://finance.yahoo.com/news/5-large-drug-stocks-watch-104700001.html", "title": "5 Large Drug Stocks to Watch as Industry Recovers", "summary": "R&D innovation is likely to remain a major focus area in 2025. In the Large-Cap Pharmaceuticals industry, AbbVie (ABBV), Novo Nordisk (NVO), Novartis (NVS), Pfizer (PFE) and Bayer (BAYRY) are worth retaining in one's portfolio", "published_at": "2025-03-25T10:47:00Z", "sentiment": "negative", "confidence": 0.9992}
{"id": "19676e97-2f17-323b-9657-736f362e0ee3", "ticker": "BAYN.DE", "url": "https://www.investopedia.com/bayer-stock-slumps-after-firm-ordered-to-pay-more-than-usd2b-in-latest-roundup-case-11702091", "title": "Bayer Stock Slumps After Firm Ordered To Pay More Than $2B in Latest Roundup Case", "summary": "Bayer was ordered to pay more than $2 billion by a jury in a Georgia state court in the latest legal case surrounding alleged cancer risk tied to its Roundup weed killer.", "published_at": "2025-03-24T16:56:30Z", "sentiment": "positive", "confidence": 0.9307}
{"id": "ad68fd4c-e99d-32e2-8faa-70c3454060fc", "ticker": "BAYN.DE", "url": "https://www.wsj.com/health/pharma/bayer-kumquat-biosciences-team-up-on-new-potential-cancer-drug-16df49dd?siteid=yhoof2&yptr=yahoo", "title": "Bayer, Kumquat Biosciences Team Up on New Potential Cancer Drug", "summary": "Under the global exclusive license deal, Kumquat will be responsible for the Phase 1a study of its inhibitor and Bayer will take the drug to market.", "published_at": "2025-08-12T07:11:00Z", "sentiment": "negative", "confidence": 1.0}
{"id": "a6c9f4f1-3b8a-3438-a829-3fd281658976", "ticker": "BAYN.DE", "url": "https://finance.yahoo.com/news/dnli-tops-q2-earnings-expects-121800559.html", "title": "DNLI Tops on Q2 Earnings, Expects Decree on Hunter Syndrome Drug in '26", "summary": "Denali Therapeutics posts narrower-than-expected Q2 loss. The company advances multiple rare disease therapies toward potential approvals.", "published_at": "2025-08-12T12:18:00Z", "sentiment": "positive", "confidence": 0.9393}
